期刊文献+

TAM受体检测评估COPD患者严重程度的研究

Significance of TAM receptor detection in the severity assessment of patients with chronic obstructive pulmonary disease
下载PDF
导出
摘要 目的探讨TAM受体(sAxl、sTyr03、sMer)检测评估慢性阻塞性肺疾病(COPD)患者严重程度的意义。方法选择2015年1月至2018年1月宁夏回族自治区人民医院呼吸科收治的468例COPD患者作为COPD组,另收集同期该院400例体检健康者作为健康对照组,检测COPD组(Ⅰ、Ⅱ、Ⅲ、Ⅳ期)及健康对照组血浆中sAxl、sTyr03、sMer水平,分析其与临床指标的关系,并采用Logistic回归分析COPD的危险因素。结果COPD组血浆中sAxl、sTyr03、sMer水平显著低于健康对照组,差异有统计学意义(P<0.05);COPD组Ⅰ、Ⅱ、Ⅲ、Ⅳ期血浆中sTyr03水平差异无统计学意义(P>0.05);COPD组Ⅰ、Ⅱ、Ⅲ、Ⅳ期血浆中sAxl、sMer水平依次下降,差异有统计学意义(P<0.05)。血浆sAxl与COPD患者年龄、第一秒用力呼气容积(FEV1)/用力肺活量(FVC)、体质量指数(BMI)、第一秒用力呼气容积占预计值的百分比(FEV1%)呈相关性,血浆sMer、sTyr03与患者FEV1%呈相关性。Logistic回归分析显示,COPD分期、sAxl、sTyr03和sMer是COPD的危险因素。结论sAxl、sMer、sTyr03在COPD患者血浆中明显降低,且sAxl、sMer水平与COPD严重程度密切相关,sAxl、sMerTAM受体可作为评估COPD患者严重程度的标志物。 Objective To investigate the significance of TAM receptor(sAxl、sTyr03、sMer) detection in the severity assessment of patients with chronic obstructive pulmonary disease (COPD).Methods A total of 468 COPD patients as COPD group admitted to the Respiratory Department and 400 healthy people as healthy control group in People′s Hospital of Ningxia Hui Autonomous Region from January 2015 to January 2018 were selected.The concentrations of sAxl,sTyr03 and sMer in the plasma of the COPD group (stage Ⅰ,Ⅱ,Ⅲ,Ⅳ) and the healthy control group were measured,and its correlation with the clinical parameters.Then the risk factors related to COPD were determined by Logistic regression analysis.Results The concentrations of sAxl,sTyr03 and sMer in the plasma of COPD group were significantly lower than those in the healthy control group ( P <0.05).The plasma concentrations of sAxl and sMer in stage Ⅰ,Ⅱ,Ⅲ,Ⅳ of COPD group decreased in turn,with statistical difference ( P <0.05),while no difference was found in sTyr03 ( P >0.05).Logistic regression analysis showed that plasma sAxl was associated with age,BMI,and FEV1/FVC in patients with COPD ( P <0.05).Plasma sAxl and sMer were positively correlated with patient FEV1%,and plasma sTyr03 was negatively correlated with patient FEV1%( P < 0.05 ).Logistic ragression analysis showed that plasma sAxl,sTyr03,sMer and COPD stages were risk factors for COPD ( P <0.05).Conclusion The levels of sAxl,sMer and sTyr03 in plasma of COPD patients are significantly decreased,and the levels of sAxl and sMer are closely related to the severity of COPD.sAxl and sMer TAM receptors can be used as markers to evaluate the severity of COPD patients.
作者 李富荣 樊瑞军 邓丽 LI Furong;FAN Ruijun;DENG Li(Department of Clinical Medical Laboratory Diagnostic Center,People′s Hospital of Ningxia Hui Autonomous Region,Yinchuan,Ningxia 750002,China)
出处 《国际检验医学杂志》 CAS 2019年第13期1569-1573,共5页 International Journal of Laboratory Medicine
关键词 TAM受体 慢性阻塞性肺疾病 sAxl sTyr03 sMer TAM receptor chronic obstructive pulmonary disease sAxl sTyr03 sMer
  • 相关文献

参考文献10

二级参考文献87

  • 1曹国强,钱桂生,林莉,崔社怀.慢性阻塞性肺疾病大鼠肺组织细胞凋亡和增殖的变化[J].中华结核和呼吸杂志,2005,28(3):169-172. 被引量:16
  • 2汤翠英,林琳,许银姬.培土生金综合治疗对慢性阻塞性肺病稳定期患者呼吸肌疲劳的影响[J].成都中医药大学学报,2006,29(4):12-16. 被引量:18
  • 3Lindstrtim FD, Eriksson P, Tejle K, et al. IgG subclasses ofan- ti-SS-A/Ro in patients with primary Sjtigren's syndrome. Clin Im- munol Immunopathol, 1994, 73: 358-361.
  • 4Takahashi H, Yamamoto M, Suzuki C, et al. The birthday of a new syndrome: IgC,4-related diseases constitute a clinical entity.Autoimmun Rev, 2010, 9: 591-594.
  • 5Vaglio A, Zwerina J. IgC,4-related disease. N Engl J Med, 2012, 366: 1646, 1646-1647.
  • 6Vilali C, Bombardieri S, ]onsson R, et al. Classification criteria for Sjt gren's syndrome: a revised version of the European crite- ria proposed by the American-European Consensus Group. Ann Rheum Dis, 2002, 61: 554-558.
  • 7Liu Y, Li J. Preferentially immunoglobulin (IgG) subclasses pro- duction in primary Sj0gren's syndrome patients. Clin Chem Lab Med, 2011, 50: 345-349.
  • 8Erikssen P, Alraroth G, Denneberg T, et al. IgG2 deficiency in primary Sjt gren's syndrome and hypergammaglobulinemie pur- pura. Clin Immund Immunopathd, 1994, 70: 60-65.
  • 9Yamamoto M, Tabcya T, Naishiro Y, et al. Value of serum IgC,4 in the diagnosis of IgC.4-related disease and in differentiation from rheumatic diseases and other diseases. Med Rheumatol, 2012, 22: 419-425.
  • 10Umehara H, Okazaki K, Masaki Y, et al. A novel clinical enti- ty, IgG4-related disease (IgC.4RD): general concept and details. Mod Rheumatd, 2012, 22: 1-14.

共引文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部